Cyra Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cyra Patel has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Meru Sheel
The University of Sydney
8 shared publications Akeem Ali
World Health Organization
4 shared publications- Gemma L. Saravanos
Susan Wakil School of Nursing and Midwifery, Faculty of Medicine and Health University of Sydney Sydney NSW Australia
3 shared publications Ginny M. Sargent
National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia
3 shared publications- Maria Carolina Danovaro-Holliday
Department of Immunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland
3 shared publications - Praveena Gunaratnam
School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia
3 shared publications
Latest Publications
- Open Access
- 19 April 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (4) , e70188
The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention
Seasonal influenza causes significant morbidity and mortality in Australia. Despite long‐standing recommendations for influenza vaccination and nationally funded programs for higher risk age or population groups, coverage remains suboptimal, especially among children. Introduction of the intranasal live attenuated influenza vaccine (LAIV) in 2026 offers an additional safe and effective needle‐free vaccine option. Easier administration may improve access by making delivery by a range of health care providers possible. This perspective article outlines the evidence supporting the use of the LAIV and its potential to improve vaccination uptake among children in Australia.
- 19 April 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (4) , e70188
Open AccessThe Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention
Seasonal influenza causes significant morbidity and mortality in Australia. Despite long‐standing recommendations for influenza vaccination and nationally funded programs for higher risk age or population groups, coverage remains suboptimal, especially among children. Introduction of the intranasal live attenuated influenza vaccine (LAIV) in 2026 offers an additional safe and effective needle‐free vaccine option. Easier administration may improve access by making delivery by a range of health care providers possible. This perspective article outlines the evidence supporting the use of the LAIV and its potential to improve vaccination uptake among children in Australia.
- Open Access
- 3 February 2026
- Published by Springer Nature in Research Square
Strengthening Immunisation Data Systems: a mixed methods evaluation of the Lao Electronic Immunisation Registry
The Lao People's Democratic Republic introduced an electronic immunisation registry (EIR) for routine immunisation in 2022. This study evaluated the EIR during its early stages to inform ongoing implementation and future use. We used a multi-method approach that involved five data sources: document review; health facility survey; key informant interviews; workflow observation; and data quality assessments. We surveyed 26 healthcare workers across 26 facilities. Respondents’ perceptions of the EIR were largely positive, though views on workload were mixed, and most indicated insufficient training and ongoing needs in data analysis and problem-solving. Only half consider infrastructure adequate. Eighteen stakeholder interviews highlighted strong uptake of the EIR and improved ability to generate reports and identify under-immunised children, but also persistent data gaps, limited data use, staff shortages, reliance on development partners, and the need for stronger government ownership, supervision, and a clear long-term roadmap. Data quality assessment of 849,055 non-duplicate vaccination events showed high levels of missing or invalid data and low timeliness of birth and vaccination registration; across four facilities, the EIR captured more doses than paper registers and district reports. This evaluation showed that EIR is feasible and acceptable, but individual and system-level barriers, particularly workforce capacity and capability, digital infrastructure, governance, and financing, must be addressed to realise its impact on vaccination coverage, underscoring the need for future implementation research to optimise EIR use in Lao PDR and similar settings.
- 3 February 2026
- Published by Springer Nature in Research Square
Open AccessStrengthening Immunisation Data Systems: a mixed methods evaluation of the Lao Electronic Immunisation Registry
The Lao People's Democratic Republic introduced an electronic immunisation registry (EIR) for routine immunisation in 2022. This study evaluated the EIR during its early stages to inform ongoing implementation and future use. We used a multi-method approach that involved five data sources: document review; health facility survey; key informant interviews; workflow observation; and data quality assessments. We surveyed 26 healthcare workers across 26 facilities. Respondents’ perceptions of the EIR were largely positive, though views on workload were mixed, and most indicated insufficient training and ongoing needs in data analysis and problem-solving. Only half consider infrastructure adequate. Eighteen stakeholder interviews highlighted strong uptake of the EIR and improved ability to generate reports and identify under-immunised children, but also persistent data gaps, limited data use, staff shortages, reliance on development partners, and the need for stronger government ownership, supervision, and a clear long-term roadmap. Data quality assessment of 849,055 non-duplicate vaccination events showed high levels of missing or invalid data and low timeliness of birth and vaccination registration; across four facilities, the EIR captured more doses than paper registers and district reports. This evaluation showed that EIR is feasible and acceptable, but individual and system-level barriers, particularly workforce capacity and capability, digital infrastructure, governance, and financing, must be addressed to realise its impact on vaccination coverage, underscoring the need for future implementation research to optimise EIR use in Lao PDR and similar settings.
- Open Access
- 17 September 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 1-27
Data use for immunisation decision-making and the role of an electronic immunisation register in Vanuatu
- 17 September 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 1-27
Open AccessData use for immunisation decision-making and the role of an electronic immunisation register in Vanuatu
- Open Access
- 8 July 2025
- Vol. 20 (7) , e0317327
The association between routine immunisation and COVID-19 vaccination in small Island developing states.
Understanding the link between routine immunisation (RI) performance and vaccination during an epidemic can provide insights on health systems resilience and investments to strengthen health systems. We examined the relationship between RI performance and COVID-19 vaccination coverage in small island developing states (SIDS). We analysed immunisation and health system performance data in 55 SIDS. Our primary outcome was COVID-19 vaccination coverage at four timepoints (June 2021, December 2021, June 2022 and December 2022). We examined associations with coverage of six childhood immunisations (5-year mean annual coverage for 2015-2019), pandemic-related disruptions to RI, new vaccine introductions, health system performance measures, and economic and demographic characteristics. We calculated Spearman correlation coefficients (r) with p-values (p < 0.05 considered significant) and 95% confidence intervals for continuous variables and mean COVID-19 vaccination coverage by categorical variables. COVID-19 vaccination coverage was higher in countries that sustained pre-pandemic RI coverage during the pandemic, and where HPV, influenza and measles-containing (second dose) vaccines had been introduced. There were weak correlations (|r| < 0.4) between coverage of COVID-19 vaccination and RI, with a few exceptions of moderate correlations with the birth dose of hepatitis B vaccine (June 2022: r = 0.421, p = 0.007; December 2022: r = 0.438, p = 0.005) and first dose of measles vaccine (December 2021: r = 0.420, p = 0.002). COVID-19 vaccination coverage was strongly correlated with the density of physicians (June 2021: 0.897, p < 0.001; December 2021: 0.785, p < 0.001) and moderately correlated with that of nurses and midwives (June 2021: 0.630, p = 0.001; December 2021: 0.605, p = 0.002). COVID-19 vaccination coverage was lower in SIDS with lower country income and development status. Countries that achieved high COVID-19 vaccination coverage also sustained RI coverage during the pandemic, demonstrating health system resilience. Our findings highlight the importance of having sufficient skilled health professionals and experience in introducing new vaccines targeting different age groups into national programs, particularly in small island settings.
- 8 July 2025
- Vol. 20 (7) , e0317327
Open AccessThe association between routine immunisation and COVID-19 vaccination in small Island developing states.
Understanding the link between routine immunisation (RI) performance and vaccination during an epidemic can provide insights on health systems resilience and investments to strengthen health systems. We examined the relationship between RI performance and COVID-19 vaccination coverage in small island developing states (SIDS). We analysed immunisation and health system performance data in 55 SIDS. Our primary outcome was COVID-19 vaccination coverage at four timepoints (June 2021, December 2021, June 2022 and December 2022). We examined associations with coverage of six childhood immunisations (5-year mean annual coverage for 2015-2019), pandemic-related disruptions to RI, new vaccine introductions, health system performance measures, and economic and demographic characteristics. We calculated Spearman correlation coefficients (r) with p-values (p < 0.05 considered significant) and 95% confidence intervals for continuous variables and mean COVID-19 vaccination coverage by categorical variables. COVID-19 vaccination coverage was higher in countries that sustained pre-pandemic RI coverage during the pandemic, and where HPV, influenza and measles-containing (second dose) vaccines had been introduced. There were weak correlations (|r| < 0.4) between coverage of COVID-19 vaccination and RI, with a few exceptions of moderate correlations with the birth dose of hepatitis B vaccine (June 2022: r = 0.421, p = 0.007; December 2022: r = 0.438, p = 0.005) and first dose of measles vaccine (December 2021: r = 0.420, p = 0.002). COVID-19 vaccination coverage was strongly correlated with the density of physicians (June 2021: 0.897, p < 0.001; December 2021: 0.785, p < 0.001) and moderately correlated with that of nurses and midwives (June 2021: 0.630, p = 0.001; December 2021: 0.605, p = 0.002). COVID-19 vaccination coverage was lower in SIDS with lower country income and development status. Countries that achieved high COVID-19 vaccination coverage also sustained RI coverage during the pandemic, demonstrating health system resilience. Our findings highlight the importance of having sufficient skilled health professionals and experience in introducing new vaccines targeting different age groups into national programs, particularly in small island settings.
- Open Access
- 19 June 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e65663
Strengthening Immunization Data: Protocol for the Evaluation of an Electronic Immunization Register
Background: Electronic immunization registers (EIRs) can strengthen immunization systems and, if used effectively, can lead to greater efficiency and improvements in vaccination coverage. Several low- and middle-income countries introduced EIRs for COVID-19 vaccination and are now integrating them for routine immunization. Objective: This study aims to describe the protocol used to evaluate the implementation of an EIR in the Lao People’s Democratic Republic in 2022. In addition, it seeks to identify opportunities to improve implementation, scale-up, and sustainability in the country. Methods: To evaluate the implementation of the EIR in the Lao People’s Democratic Republic, we will (1) map the EIR workflow process, (2) examine EIR user and stakeholder perspectives, and (3) assess the EIR data quality. Data will be collected and analyzed through a mixed methods approach. This evaluation will involve a document review, observation of workflows in health facilities, health facility user surveys, key informant interviews with decision makers, and an assessment of immunization data quality. This protocol details the methods for each of these components. The evidence generated will be triangulated to identify the strengths and weaknesses of the early implementation phase of the EIR, facilitators of and barriers to the implementation, and whether the introduction of the EIR has improved immunization data processes and quality compared with paper-based processes. Results: Data collection took place between April 2024 and August 2024. Data analysis is currently ongoing, with results expected to be shared with study stakeholders in October 2024. Conclusions: This early evaluation will contribute to developing a road map for the nationwide strengthening and sustainability of the EIR based on challenges and lessons learned, potentially streamlining further implementation efforts and enabling more effective use of the EIR. This paper presents a methodology for evaluating EIR implementation that can be replicated in other low- and middle-income countries implementing EIRs. International Registered Report Identifier (IRRID): DERR1-10.2196/65663
- 19 June 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e65663
Open AccessStrengthening Immunization Data: Protocol for the Evaluation of an Electronic Immunization Register
Background: Electronic immunization registers (EIRs) can strengthen immunization systems and, if used effectively, can lead to greater efficiency and improvements in vaccination coverage. Several low- and middle-income countries introduced EIRs for COVID-19 vaccination and are now integrating them for routine immunization. Objective: This study aims to describe the protocol used to evaluate the implementation of an EIR in the Lao People’s Democratic Republic in 2022. In addition, it seeks to identify opportunities to improve implementation, scale-up, and sustainability in the country. Methods: To evaluate the implementation of the EIR in the Lao People’s Democratic Republic, we will (1) map the EIR workflow process, (2) examine EIR user and stakeholder perspectives, and (3) assess the EIR data quality. Data will be collected and analyzed through a mixed methods approach. This evaluation will involve a document review, observation of workflows in health facilities, health facility user surveys, key informant interviews with decision makers, and an assessment of immunization data quality. This protocol details the methods for each of these components. The evidence generated will be triangulated to identify the strengths and weaknesses of the early implementation phase of the EIR, facilitators of and barriers to the implementation, and whether the introduction of the EIR has improved immunization data processes and quality compared with paper-based processes. Results: Data collection took place between April 2024 and August 2024. Data analysis is currently ongoing, with results expected to be shared with study stakeholders in October 2024. Conclusions: This early evaluation will contribute to developing a road map for the nationwide strengthening and sustainability of the EIR based on challenges and lessons learned, potentially streamlining further implementation efforts and enabling more effective use of the EIR. This paper presents a methodology for evaluating EIR implementation that can be replicated in other low- and middle-income countries implementing EIRs. International Registered Report Identifier (IRRID): DERR1-10.2196/65663
- Open Access
The association between routine immunisation and COVID-19 vaccination in small island developing states
Objectives: Understanding the link between routine immunisation (RI) performance and vaccination during an epidemic can provide insights on health systems resilience and investments to strengthen health systems. We examined the relationship between RI performance and COVID-19 vaccination coverage in small island developing states (SIDS). Methods: COVID-19 vaccination coverage at four timepoints (June 2021, December 2021, June 2022 and December 2022) in 55 SIDS was our primary outcome. We examined associations with coverage of six childhood immunisations (5-year mean annual coverage for 2015–2019), pandemic-related disruptions to RI, new vaccine introductions, health system performance measures, and economic and demographic characteristics. We calculated Spearman correlations for continuous variables and mean COVID-19 vaccination coverage by categorical variables. Findings: We found COVID-19 vaccination coverage was higher in countries that sustained RI coverage during the pandemic, and where HPV, influenza and measles-containing (second dose) vaccines had been introduced. There were weak correlations (|r|<0.4) between coverage of COVID-19 vaccination and RI, with a few exceptions of moderate correlations with the birth dose of hepatitis B vaccine (June 2022: r=0.421, p=0.007; December 2022: r=0.438, p=0.005) and first dose of measles vaccine (December 2021: r=0.420, p=0.002). COVID-19 vaccination coverage was strongly correlated with the density of physicians (June 2021: 0.897, p<0.001; December 2021: 0.785, p<0.001) and moderately correlated with that of nurses and midwives (June 2021: 0.630, p=0.001; December 2021: 0.605, p=0.002). COVID-19 vaccination coverage was lower in SIDS with lower country income and development status. Conclusions: Countries that achieved high COVID-19 vaccination coverage maintained RI coverage, demonstrating health system resilience. Our findings highlight the importance of having sufficient skilled health professionals and experience in introducing new vaccines targeting different age groups into national programs, particularly in small island settings.
Open AccessThe association between routine immunisation and COVID-19 vaccination in small island developing states
Objectives: Understanding the link between routine immunisation (RI) performance and vaccination during an epidemic can provide insights on health systems resilience and investments to strengthen health systems. We examined the relationship between RI performance and COVID-19 vaccination coverage in small island developing states (SIDS). Methods: COVID-19 vaccination coverage at four timepoints (June 2021, December 2021, June 2022 and December 2022) in 55 SIDS was our primary outcome. We examined associations with coverage of six childhood immunisations (5-year mean annual coverage for 2015–2019), pandemic-related disruptions to RI, new vaccine introductions, health system performance measures, and economic and demographic characteristics. We calculated Spearman correlations for continuous variables and mean COVID-19 vaccination coverage by categorical variables. Findings: We found COVID-19 vaccination coverage was higher in countries that sustained RI coverage during the pandemic, and where HPV, influenza and measles-containing (second dose) vaccines had been introduced. There were weak correlations (|r|<0.4) between coverage of COVID-19 vaccination and RI, with a few exceptions of moderate correlations with the birth dose of hepatitis B vaccine (June 2022: r=0.421, p=0.007; December 2022: r=0.438, p=0.005) and first dose of measles vaccine (December 2021: r=0.420, p=0.002). COVID-19 vaccination coverage was strongly correlated with the density of physicians (June 2021: 0.897, p<0.001; December 2021: 0.785, p<0.001) and moderately correlated with that of nurses and midwives (June 2021: 0.630, p=0.001; December 2021: 0.605, p=0.002). COVID-19 vaccination coverage was lower in SIDS with lower country income and development status. Conclusions: Countries that achieved high COVID-19 vaccination coverage maintained RI coverage, demonstrating health system resilience. Our findings highlight the importance of having sufficient skilled health professionals and experience in introducing new vaccines targeting different age groups into national programs, particularly in small island settings.
- 18 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 998-1004
Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions
Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (ie, prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety. In people receiving prednisone 20 mg/day), antibody titres and seropositivity are reduced, whereas the impact of low- to medium-dose glucocorticoids (7 to 20 mg/day) on vaccine efficacy remains inconclusive. Due to inconsistent paediatric dosing regimens, data is insufficient to support a unified “high-dose” glucocorticoid threshold. Non-live vaccines are well tolerated in patients receiving glucocorticoids with rheumatic/inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those with severe immunodeficiencies. Clinicians should consider individual risk-benefit profiles, rather than following strict dosing thresholds, when curating immunisation programs for patients prescribed glucocorticoids.
- 18 December 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 998-1004
Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions
Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (ie, prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety. In people receiving prednisone 20 mg/day), antibody titres and seropositivity are reduced, whereas the impact of low- to medium-dose glucocorticoids (7 to 20 mg/day) on vaccine efficacy remains inconclusive. Due to inconsistent paediatric dosing regimens, data is insufficient to support a unified “high-dose” glucocorticoid threshold. Non-live vaccines are well tolerated in patients receiving glucocorticoids with rheumatic/inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those with severe immunodeficiencies. Clinicians should consider individual risk-benefit profiles, rather than following strict dosing thresholds, when curating immunisation programs for patients prescribed glucocorticoids.
- Open Access
- 27 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Strengthening Immunization Data: Protocol for the Evaluation of an Electronic Immunization Register (Preprint)
BACKGROUND Electronic immunization registers (EIRs) can strengthen immunization systems and, if used effectively, can lead to greater efficiency and improvements in vaccination coverage. Several low- and middle-income countries introduced EIRs for COVID-19 vaccination and are now integrating them for routine immunization. OBJECTIVE This study aims to describe the protocol used to evaluate the implementation of an EIR in the Lao People’s Democratic Republic in 2022. In addition, it seeks to identify opportunities to improve implementation, scale-up, and sustainability in the country. METHODS To evaluate the implementation of the EIR in the Lao People’s Democratic Republic, we will (1) map the EIR workflow process, (2) examine EIR user and stakeholder perspectives, and (3) assess the EIR data quality. Data will be collected and analyzed through a mixed methods approach. This evaluation will involve a document review, observation of workflows in health facilities, health facility user surveys, key informant interviews with decision makers, and an assessment of immunization data quality. This protocol details the methods for each of these components. The evidence generated will be triangulated to identify the strengths and weaknesses of the early implementation phase of the EIR, facilitators of and barriers to the implementation, and whether the introduction of the EIR has improved immunization data processes and quality compared with paper-based processes. RESULTS Data collection took place between April 2024 and August 2024. Data analysis is currently ongoing, with results expected to be shared with study stakeholders in October 2024. CONCLUSIONS This early evaluation will contribute to developing a road map for the nationwide strengthening and sustainability of the EIR based on challenges and lessons learned, potentially streamlining further implementation efforts and enabling more effective use of the EIR. This paper presents a methodology for evaluating EIR implementation that can be replicated in other low- and middle-income countries implementing EIRs. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/65663
- 27 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessStrengthening Immunization Data: Protocol for the Evaluation of an Electronic Immunization Register (Preprint)
BACKGROUND Electronic immunization registers (EIRs) can strengthen immunization systems and, if used effectively, can lead to greater efficiency and improvements in vaccination coverage. Several low- and middle-income countries introduced EIRs for COVID-19 vaccination and are now integrating them for routine immunization. OBJECTIVE This study aims to describe the protocol used to evaluate the implementation of an EIR in the Lao People’s Democratic Republic in 2022. In addition, it seeks to identify opportunities to improve implementation, scale-up, and sustainability in the country. METHODS To evaluate the implementation of the EIR in the Lao People’s Democratic Republic, we will (1) map the EIR workflow process, (2) examine EIR user and stakeholder perspectives, and (3) assess the EIR data quality. Data will be collected and analyzed through a mixed methods approach. This evaluation will involve a document review, observation of workflows in health facilities, health facility user surveys, key informant interviews with decision makers, and an assessment of immunization data quality. This protocol details the methods for each of these components. The evidence generated will be triangulated to identify the strengths and weaknesses of the early implementation phase of the EIR, facilitators of and barriers to the implementation, and whether the introduction of the EIR has improved immunization data processes and quality compared with paper-based processes. RESULTS Data collection took place between April 2024 and August 2024. Data analysis is currently ongoing, with results expected to be shared with study stakeholders in October 2024. CONCLUSIONS This early evaluation will contribute to developing a road map for the nationwide strengthening and sustainability of the EIR based on challenges and lessons learned, potentially streamlining further implementation efforts and enabling more effective use of the EIR. This paper presents a methodology for evaluating EIR implementation that can be replicated in other low- and middle-income countries implementing EIRs. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/65663
- Open Access
- 25 July 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (7) , e0003068
Measuring what matters: Context-specific indicators for assessing immunisation performance in Pacific Island Countries and Areas
Increasing countries’ access to data can improve immunisation coverage through evidence-based decision-making. However, data collection and reporting is resource-intensive, so needs to be pragmatic, especially in low-and-middle-income countries. We aimed to identify which indicators are most important for measuring, and improving, national immunisation performance in Pacific Island Countries (PICs). We conducted an expert elicitation study, asking 13 experts involved in delivering immunisation programs, decision-makers, health information specialists, and global development partners across PICs to rate 41 indicators based on their knowledge of the feasibility and relevance of each indicator. We also asked experts their preferences for indicators to be retained or removed from a list of indicators for PICs. Experts participated in two rating rounds, with a discussion on the reasons for ratings before the second round. We calculated mean scores for feasibility and relevance, and ranked indicators based on experts’ preferences and mean scores. We used framework analysis to identify reasons for selecting indicators. Experts agreed that certain indicators were essential to measure (e.g. data use in program planning and measles vaccination coverage), but preferences varied for most indicators. Preferences to include indicators in a set of indicators for PICs moderately correlated with scores for relevance (r = 0.68) and feasibility (r = 0.56). In discussions, experts highlighted usefulness for decision-making and ease of data collection, reporting and interpretation as the main reasons driving indicator selection. Country-specific factors such as health system factors, roles and influence of various immunisation actors, and macro-level factors (namely population size, distribution and mobility) affected relevance and feasibility, leading us to conclude that a single set of indicators for all PICs is inappropriate. Rather than having a strict set of indicators that all countries must measure and report against, performance indicators should be flexible, country-specific, and selected in consultation with immunisation actors who collect and use the data.
- 25 July 2024
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 4 (7) , e0003068
Open AccessMeasuring what matters: Context-specific indicators for assessing immunisation performance in Pacific Island Countries and Areas
Increasing countries’ access to data can improve immunisation coverage through evidence-based decision-making. However, data collection and reporting is resource-intensive, so needs to be pragmatic, especially in low-and-middle-income countries. We aimed to identify which indicators are most important for measuring, and improving, national immunisation performance in Pacific Island Countries (PICs). We conducted an expert elicitation study, asking 13 experts involved in delivering immunisation programs, decision-makers, health information specialists, and global development partners across PICs to rate 41 indicators based on their knowledge of the feasibility and relevance of each indicator. We also asked experts their preferences for indicators to be retained or removed from a list of indicators for PICs. Experts participated in two rating rounds, with a discussion on the reasons for ratings before the second round. We calculated mean scores for feasibility and relevance, and ranked indicators based on experts’ preferences and mean scores. We used framework analysis to identify reasons for selecting indicators. Experts agreed that certain indicators were essential to measure (e.g. data use in program planning and measles vaccination coverage), but preferences varied for most indicators. Preferences to include indicators in a set of indicators for PICs moderately correlated with scores for relevance (r = 0.68) and feasibility (r = 0.56). In discussions, experts highlighted usefulness for decision-making and ease of data collection, reporting and interpretation as the main reasons driving indicator selection. Country-specific factors such as health system factors, roles and influence of various immunisation actors, and macro-level factors (namely population size, distribution and mobility) affected relevance and feasibility, leading us to conclude that a single set of indicators for all PICs is inappropriate. Rather than having a strict set of indicators that all countries must measure and report against, performance indicators should be flexible, country-specific, and selected in consultation with immunisation actors who collect and use the data.